2005
DOI: 10.1016/j.clp.2005.09.010
|View full text |Cite
|
Sign up to set email alerts
|

Nutrition Care for Newborns with Congenital Heart Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
54
0
13

Year Published

2009
2009
2022
2022

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 42 publications
(67 citation statements)
references
References 14 publications
0
54
0
13
Order By: Relevance
“…Even the mildest congenital heart disease is reflected in some degree of adverse effect on child growth (17) .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Even the mildest congenital heart disease is reflected in some degree of adverse effect on child growth (17) .…”
Section: Discussionmentioning
confidence: 99%
“…In addition to this, in this study, no association was verified between the types of heart disease and the anthropometric measurements investigated, whereas the literature evidences cyanotic heart disease as a cause of greater repercussions on the child's weight and length. Hence, the study indicates that the development of malnutrition in these children depends on the type and severity of the congenital cardiac malformation (17) .…”
mentioning
confidence: 99%
“…Somandose a isso, a má absorção presente nas crianças cardiopatas limita significativamente a tolerância alimentar e afeta a capacidade da criança para maximizar o consumo calórico, bem como diminui a absorção de nutrientes (3). Dessa forma, a desnutrição é constante nessas crianças, independente da natureza do defeito cardíaco e da presença ou não de cianose (4).…”
Section: Introductionunclassified
“…Teamwork, advancing clinical skills, autonomy, and professional development were modeled by mentors in this new and developing role. Educational tools for parents, nutritional support [24], protocol development, and research were career achievements. The home surveillance monitoring program (HMP)was developed for high risk interstage time period for CHD between stage 1 and stage 2 palliation utilizing a home scale, pulse oximeter, binder, and close interstage clinical management [25].…”
Section: Third Born (1970)mentioning
confidence: 99%